Your browser doesn't support javascript.
loading
Association between hypogammaglobulinaemia and severe infections during induction therapy in ANCA-associated vasculitis: from J-CANVAS study.
Omura, Satoshi; Kida, Takashi; Noma, Hisashi; Sunaga, Atsuhiko; Kusuoka, Hiroaki; Kadoya, Masatoshi; Nakagomi, Daiki; Abe, Yoshiyuki; Takizawa, Naoho; Nomura, Atsushi; Kukida, Yuji; Kondo, Naoya; Yamano, Yasuhiko; Yanagida, Takuya; Endo, Koji; Hirata, Shintaro; Matsui, Kiyoshi; Takeuchi, Tohru; Ichinose, Kunihiro; Kato, Masaru; Yanai, Ryo; Matsuo, Yusuke; Shimojima, Yasuhiro; Nishioka, Ryo; Okazaki, Ryota; Takata, Tomoaki; Ito, Takafumi; Moriyama, Mayuko; Takatani, Ayuko; Miyawaki, Yoshia; Ito-Ihara, Toshiko; Yajima, Nobuyuki; Kawaguchi, Takashi; Fukuda, Wataru; Kawahito, Yutaka.
Afiliação
  • Omura S; Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Kida T; Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
  • Noma H; Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Sunaga A; Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan.
  • Kusuoka H; Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Kadoya M; Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
  • Nakagomi D; Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Abe Y; Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
  • Takizawa N; Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
  • Nomura A; Department of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan.
  • Kukida Y; Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.
  • Kondo N; Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Japan.
  • Yamano Y; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
  • Yanagida T; Department of Rheumatology, Japanese Red Cross Society Kyoto Daini Hospital, Kyoto, Japan.
  • Endo K; Department of Nephrology, Kyoto Katsura Hospital, Kyoto, Japan.
  • Hirata S; Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan.
  • Matsui K; Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
  • Takeuchi T; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
  • Ichinose K; Department of General Internal Medicine, Tottori Prefectural Central Hospital, Tottori, Japan.
  • Kato M; Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
  • Yanai R; Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Hyogo, Japan.
  • Matsuo Y; Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Shimojima Y; Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Nishioka R; Department of Rheumatology, Shimane University Faculty of Medicine, Shimane, Japan.
  • Okazaki R; Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Takata T; Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Ito T; Department of Rheumatology, Tokyo Kyosai Hospital, Tokyo, Japan.
  • Moriyama M; Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
  • Takatani A; Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
  • Miyawaki Y; Department of Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
  • Ito-Ihara T; Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
  • Yajima N; Division of Gastroenterology and Nephrology, Tottori University, Yonago, Japan.
  • Kawaguchi T; Division of Nephrology, Shimane University Hospital, Shimane, Japan.
  • Fukuda W; Department of Rheumatology, Shimane University Faculty of Medicine, Shimane, Japan.
  • Kawahito Y; Rheumatic Disease Center, Sasebo Chuo Hospital, Nagasaki, Japan.
Rheumatology (Oxford) ; 62(12): 3924-3931, 2023 12 01.
Article em En | MEDLINE | ID: mdl-36961329
ABSTRACT

OBJECTIVES:

To investigate the association between decreased serum IgG levels caused by remission-induction immunosuppressive therapy of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and the development of severe infections.

METHODS:

We conducted a retrospective cohort study of patients with new-onset or severe relapsing AAV enrolled in the J-CANVAS registry, which was established at 24 referral sites in Japan. The minimum serum IgG levels up to 24 weeks and the incidence of severe infection up to 48 weeks after treatment initiation were evaluated. After multiple imputations for all explanatory variables, we performed the multivariate analysis using a Fine-Gray model to assess the association between low IgG (the minimum IgG levels <500 mg/dl) and severe infections. In addition, the association was expressed as a restricted cubic spline (RCS) and analysed by treatment subgroups.

RESULTS:

Of 657 included patients (microscopic polyangiitis, 392; granulomatosis with polyangiitis, 139; eosinophilic granulomatosis with polyangiitis, 126), 111 (16.9%) developed severe infections. The minimum serum IgG levels were measured in 510 patients, of whom 77 (15.1%) had low IgG. After multiple imputations, the confounder-adjusted hazard ratio of low IgG for the incidence of severe infections was 1.75 (95% confidence interval 1.03-3.00). The RCS revealed a U-shaped association between serum IgG levels and the incidence of severe infection with serum IgG 946 mg/dl as the lowest point. Subgroup analysis showed no obvious heterogeneity between treatment regimens.

CONCLUSION:

Regardless of treatment regimens, low IgG after remission-induction treatment was associated with the development of severe infections up to 48 weeks after treatment initiation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Churg-Strauss / Granulomatose com Poliangiite / Agamaglobulinemia / Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos / Poliangiite Microscópica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Churg-Strauss / Granulomatose com Poliangiite / Agamaglobulinemia / Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos / Poliangiite Microscópica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article